Amicus Therapeutics Files Supplemental Proxy, Disclosing Four Lawsuits Challenging BioMarin Merger Ahead of Vote

summarizeSummary

Amicus Therapeutics filed additional proxy materials, revealing four shareholder lawsuits challenging the BioMarin acquisition and providing extensive new financial projections and merger background details ahead of the March 3rd vote.

check_boxKey Events

• Four Shareholder Lawsuits Disclosed

  Amicus Therapeutics revealed four purported stockholder lawsuits filed between January 22 and February 13, 2026, alleging material omissions and misleading disclosures in the proxy statements for the BioMarin merger. These lawsuits seek injunctive relief to prevent the merger or claim damages.

• Enhanced Merger Background Details

  The filing provides additional details on the merger's background, including the formation of a Transactions Committee, initial discussions with BioMarin, outreach to other potential bidders (who declined), and the resolution of Lupin and Aurobindo litigation.

• Updated Financial Projections and Advisor Analysis

  Extensive new and clarified financial projections (July, November, December cases) and detailed methodologies used by financial advisors (Centerview and Goldman Sachs) in their fairness opinions have been added, providing greater transparency on valuation assumptions.

• Critical Shareholder Vote Approaching

  These supplemental materials are filed ahead of the special meeting of stockholders on March 3, 2026, where shareholders will vote on the proposed $14.50 per share cash acquisition by BioMarin Pharmaceutical Inc.

auto_awesomeAnalysis

This DEFA14A filing provides crucial supplemental information to the definitive proxy statement for the upcoming BioMarin acquisition vote on March 3, 2026. The company has disclosed four purported stockholder lawsuits filed between January 22 and February 13, 2026, alleging material omissions and misleading disclosures in the proxy materials, seeking to enjoin the merger or claim damages. While Amicus believes these claims are without merit, such litigation introduces potential delays or complications to the deal. Additionally, the filing includes extensive new details and clarifications regarding the merger's background, the financial analyses performed by advisors, and updated financial projections, which aim to enhance transparency and address potential shareholder concerns ahead of the critical vote. Investors should review these disclosures carefully as they provide a more complete picture of the merger process and associated risks.